uniQure (NASDAQ:QURE) Director Sells $73,765.56 in Stock

uniQure N.V. (NASDAQ:QURE) Director Robert Gut sold 2,726 shares of uniQure stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total transaction of $73,765.56. Following the completion of the transaction, the director owned 32,259 shares of the company’s stock, valued at $872,928.54. This represents a 7.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Gut also recently made the following trade(s):

• On Wednesday, June 10th, Robert Gut sold 7,552 shares of uniQure stock. The shares were sold at an average price of $26.05, for a total transaction of $196,729.60.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $27.57 on Monday. The firm has a fifty day moving average price of $22.52 and a two-hundred day moving average price of $21.76. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -7.92 and a beta of 0.98.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Analysts anticipate that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Trading of uniQure

A number of hedge funds have recently made changes to their positions in QURE. Woodline Partners LP lifted its holdings in shares of uniQure by 25.0% during the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock worth $1,864,000 after acquiring an additional 35,175 shares during the last quarter. Legal & General Group Plc bought a new stake in shares of uniQure during the 2nd quarter worth $497,000. Marshall Wace LLP lifted its holdings in shares of uniQure by 276.5% during the 2nd quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock worth $3,108,000 after acquiring an additional 163,749 shares during the last quarter. California State Teachers Retirement System bought a new stake in shares of uniQure during the 2nd quarter worth $540,000. Finally, Ameriprise Financial Inc. lifted its holdings in shares of uniQure by 38.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after acquiring an additional 212,218 shares during the last quarter. 78.83% of the stock is owned by institutional investors.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
• Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
• Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

Analyst Upgrades and Downgrades

QURE has been the subject of several analyst reports. The Goldman Sachs Group raised their price target on shares of uniQure from $9.00 to $10.00 and gave the company a “neutral” rating in a report on Monday, April 20th. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and raised their price target for the company from $12.00 to $35.00 in a report on Wednesday, March 11th. Chardan Capital raised their price target on shares of uniQure from $31.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, April 30th. TD Cowen reissued a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.83.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.